IgA Tissue Transglutaminase Antibodies at Different cut-offs in the Evaluation of Possible Celiac Patients

Gabriel Samasca¹, Pirvan Alexandru², Genel Sur², Abrudan Carmen³, Iulia Lupan^4, and Diana Deleanu¹

¹Department of Immunology and Allergology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

²Department of Pediatrics II, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

³Emergency Hospital for Children, Cluj-Napoca, Romania

⁴Institute for Interdisciplinary Research in Bio-Nano-Science, “Babes-Bolyai” University, Cluj-Napoca, Romania

Cite this paper:
Gabriel Samasca, Pirvan Alexandru, Genel Sur, Abrudan Carmen, Iulia Lupan and Diana Deleanu. IgA Tissue Transglutaminase Antibodies at Different cut-offs in the Evaluation of Possible Celiac Patients. International Journal of Celiac Disease. 2016; 4(2):61-63. doi: 10.12691/ijcd-4-2-10

Abstract

The celiac disease screening with IgA tissue transglutaminase antibodies depends on the cut-off reaction, therefore many patients with values less but close to the cut-off may be undiagnosed. Material and Method. We conducted the CD screening with IgA tissue transglutaminase antibodies in a group of 1616 children during 2014 at a cut-off of 25 U/ml and at a cut-off of 10 U/ml. We also wanted to compare our results with IgA tissue transglutaminase antibodies prevalence from other countries. Results. We found a IgA tissue transglutaminase antibodies prevalence rate of 3% for values higher 25 U/ml and a IgA tissue transglutaminase antibodies prevalence rate of 1.6% for values between 10-25 U/ml. A prevalence of 13.6% for IgA tissue transglutaminase antibodies was observed in , and . Conclusions. We observed a 4.6% IgA tissue transglutaminase antibodies prevalence at a cut-off of 10 U/ml. Prevalence of IgA tissue transglutaminase antibodies from Romania is lowered compared with other European countries.

Keywords:
celiac disease screening cut-off

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Husby S, Koletzko S, Korponay-Szabó IR, Mearin ML, Phillips A, Shamir R, et al. European Society for Pediatric Gastroen Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012;54:136-160.
[2]	Webb C, Norström F, Myléus A, Ivarsson A, Halvarsson B, Högberg L, et al. Celiac Disease Can be Predicted by High Levels of Anti-Tissue Transglutaminase Antibodies in Population-Based Screening. J Pediatr Gastroenterol Nutr. 2015:60:787-791.
[3]	Fasano A, Araya M, Bhatnagar S, Cameron D, Catassi C, Dirks M et al. Consensus guidelines. J Pediatr Gastroenterol Nutr 2008; 47:214-219.
[4]	Samasca G, Sur G, Lupan I. Current Trends and Investigative Developments in Celiac Disease. Immunological Investigation 2013; 42:273-284.
[5]	Hojsak I, Shamir R. Tissue transglutaminase antibodies in celiac disease: focus on the pediatric population. Drugs Today (Barc). 2011;47:683-691.
[6]	Gabriel S, Mihaela I, Angela B, Mariana A, Doru D. Prevalence of IgA antitissue transglutaminase antibodies in children with type 1 diabetes mellitus. J Clin Lab Anal. 2011;25:156-161.
[7]	Waisbourd-Zinman O, Hojsak I, Rosenbach Y, Mozer-Glassberg Y, Shalitin S, Phillip M, et al. Spontaneous normalization of anti-tissue transglutaminase antibody levels is common in children with type 1 diabetes mellitus. Dig Dis Sci. 2012;57:1314-1320.
[8]	Samaşca G, Iancu M, Farcău D, Butnariu A, Pop T, Pîrvan A, et al. IgA anti-tissue transglutaminase antibodies, first line in the diagnosis of celiac disease. Clin Lab. 2011;57:695-701.
[9]	Makovicky P, Rimarova K, Boor A, Makovicky P, Vodicka P, Samasca G, et al. Correlation between antibodies and histology in celiac disease: incidence of celiac disease is higher than expected in the pediatric population. Mol Med Rep. 2013;8:1079-1083.
[10]	Husby S, Murray JA. Diagnosing coeliac disease and the potential for serological markers. Nat Rev Gastroenterol Hepatol. 2014;11:655-663.
[11]	Health Quality Ontario. Clinical utility of serologic testing for celiac disease in ontario: an evidence-based analysis. Ont Health Technol Assess Ser. 2010;10:1-111.
[12]	Lerner A, Jeremias P, Matthias M. Outside of Normal Limits: False Positive/Negative Anti TG2 Autoantibodies. International Journal of Celiac Disease. 2015:3:87-90.
[13]	Dalgic B1, Sari S, Basturk B, Ensari A, Egritas O, Bukulmez A, et al. Prevalence of celiac disease in healthy Turkish school children. Am J Gastroenterol. 2011;106:1512-1517.
[14]	Farahmand F, Modaresi V, Najafi M, Khodadad A, Moetamed F, Modarres Z. Prevalence of celiac disease in Iranian children with recurrent abdominal pain referred to a pediatric referral center. Iran J Pediatr. 2011;21:33-38.
[15]	Mora M, Litwin N, Toca Mdel C, Azcona MI, Solís Neffa R, Battiston F, et al. Prevalence of celiac disease: multicentric trial among pediatric population from five urban districts in Argentina. Arch Argent Pediatr. 2012;110:490-496.
[16]	Alessandrini S, Giacomoni E, Muccioli F. Mass population screening for celiac disease in children: the experience in Republic of San Marino from 1993 to 2009. Ital J Pediatr. 2013;39:67.
[17]	Chogle A, Saps M. Yield and cost of performing screening tests for constipation in children. Can J Gastroenterol. 2013;27:e35-38.
[18]	Fortunato F, Martinelli D, Cozza V, Ciavarella P, Valente A, Cazzato T, et al. Italian family paediatricians' approach and management of celiac disease: a cross-sectional study in Puglia Region, 2012. BMC Gastroenterol. 2014;14:38.
[19]	Jansen MA, Tromp II, Kiefte-de Jong JC, Jaddoe VW, Hofman A, Escher JC, et al. Infant feeding and anti-tissue transglutaminase antibody concentrations in the Generation R Study. Am J Clin Nutr. 2014;100:1095-1101.
[20]	Agardh D, Lee HS, Kurppa K, Simell V, Aronsson CA, Jörneus O, et al. Clinical features of celiac disease: a prospective birth cohort. Pediatrics. 2015;135:627-634.